Micromonovision by IOL Implantation

Concept and Rationale

• Preserving stereoacuity more effectively than full monovision
• Providing useful intermediate/near functional vision
• Being better tolerated neurologically through binocular summation

Patient Selection

Technique: IOL Power Calculation and Targeting

1. Determine Eye Dominance

• Identify the dominant eye for distance (typically right in right-handed individuals, but always test clinically).
• Target dominant eye: plano (0.00 D) or slight myopia (−0.25 D).

2. Non-Dominant Eye Target Refraction

3. IOL Power Selection

• Use a modern biometric formula (Barrett Universal II, Kane, or Holladay 2) for accurate power calculation.
• To achieve −0.75 D in the non-dominant eye: select an IOL power approximately 1.0–1.5 D less than the emmetropic IOL power (exact adjustment depends on the A-constant and axial length; higher myopia per diopter IOL change occurs in shorter eyes).
• Verify with intraoperative aberrometry (ORA/Verion) if available — especially valuable in post-refractive surgery eyes.

4. IOL Platform Choice

• Monofocal IOL (e.g., AcrySof IQ, Tecnis Monofocal, enVista): the standard choice for micromonovision; predictable, minimal dysphotopsia.
• Extended depth of focus (EDOF) IOL (e.g., Symfony, Vivity): can be combined with micromonovision to extend the range of clear vision even further — sometimes called "enhanced micromonovision".
• Multifocal IOLs are generally not combined with micromonovision (competing optical strategies).

Surgical Steps

1. Mark the dominant eye prior to surgery (e.g., a surgical marker at the limbus) to avoid mix-up.
2. Perform phacoemulsification with standard technique.
3. Dominant eye first (if bilateral sequential surgery): confirm emmetropic outcome before the non-dominant eye procedure.
4. Select IOL power for non-dominant eye to target −0.75 D (or chosen target).
5. Confirm IOL position in the capsular bag; centered optic is critical to avoid induced astigmatism/aberrations.
6. Residual astigmatism should be ≤0.50 DC in each eye; if higher, address with LRI, toric IOL, or LASIK enhancement.

Postoperative Considerations

• Neuroadaptation: Most patients adapt within 4–6 weeks; warn them of initial mild blurring at certain distances.
• Spectacle independence: ~80–90% achieve functional spectacle independence for distance and intermediate tasks with micromonovision.
• Reversibility: If not tolerated, the non-dominant eye can be targeted with a piggyback IOL or LASIK enhancement to bring it to emmetropia.
• Night driving: Some patients perceive mild blur at distance in dim light; important to counsel preoperatively.

Micromonovision vs. Other Strategies

Key Points (Kanski / Zia Principles)

• The critical distinction of micromonovision is limiting the interocular anisometropia to ≤1.25 D, preserving binocular summation and stereopsis (Kanski's Clinical Ophthalmology, 9th ed., Lens chapter).
• Preoperative simulation with a contact lens trial is considered mandatory before committing to surgical monovision of any degree.
• EDOF IOLs in both eyes with micromonovision targeting (dominant eye plano, non-dominant −0.50 D) represent a contemporary refinement offering extended intermediate range (Zia: Principles of Refractive Surgery).
• Accurate biometry and formula selection are the single most important technical factors — a postoperative refraction that misses the target by even 0.50 D can shift the patient into unplanned full monovision or bilateral distance emmetropia, defeating the strategy.

Patient Selection for Micromonovision by IOL Implantation

Overview

1. Ideal Candidate Profile

"Patients with a history of successful adaptation to monovision with eyeglasses or contact lenses are particularly well suited for this modality." — AAO BCSC Cataracts in the Adult Eye, p. 29

2. Ocular Dominance Assessment

Clinical Tests for Ocular Dominance:

• Hole-in-card (Miles) test: Patient holds a card with a small central hole at arm's length, views a distant target binocularly, then alternately closes each eye — the dominant eye maintains the target in view.
• Pointing test: Patient points at a distant object binocularly; the eye that aligns with the finger when the other is closed is dominant.
• Fogging test: Add +1.50 D lens over each eye alternately during binocular viewing; the eye whose blur is less tolerated is dominant.

Caveat (Refractive Surgery, p. 44): "It can be difficult to assess which eye is the dominant eye in a preoperative patient who has blurred vision due to cataracts." Therefore, dominance testing should be performed with best-corrected vision or after initial cataract surgery in the first eye before targeting the second.

3. Preoperative Simulation — Contact Lens Trial

• Fit the non-dominant eye with a −0.75 D contact lens (or the intended target refraction) while the dominant eye is corrected to emmetropia.
• Trial period: 1–2 weeks minimum in real-world conditions (work, driving, reading).
• Assess:
  • Tolerance of interocular blur
  • Adequacy of near/intermediate vision
  • Distance vision satisfaction
  • Any symptoms of asthenopia, headache, or diplopia

"Before cataract surgery, it is also difficult to demonstrate the proposed results of monovision IOLs using contact lenses. Patients who have demonstrated success with monovision contact lenses before the development of cataracts may be well suited for this modality." — AAO BCSC Refractive Surgery, p. 44

4. Binocular Vision Evaluation

5. Absolute Contraindications

• Manifest strabismus — lack of fusional mechanisms means diplopia is likely
• Macular disease (AMD, macular edema, epiretinal membrane) — unpredictable vision quality undermines the strategy
• Optic nerve disease (glaucoma with significant field loss, optic neuritis) — monocular image quality already compromised
• Amblyopia — unequal image quality interferes with neuroadaptation
• Severe dry eye / corneal pathology — fluctuating vision impairs adaptation

"In general, patients with latent strabismus, macular disease, or optic nerve disease are poor candidates for monovision, unless they have previously done well with optical correction." — AAO BCSC Cataracts in the Adult Eye, p. 29

6. Relative Contraindications / Caution Groups

7. Informed Consent Points

1. Residual spectacle need: Reading glasses may still be required for very fine print; distance glasses occasionally for night driving.
2. Neuroadaptation period: 4–6 weeks for the brain to suppress interocular blur; transient symptoms are normal.
3. Reduced stereopsis: Minor reduction in depth perception — relevant for certain sports (cricket, tennis).
4. Reversibility: If micromonovision is not tolerated postoperatively, the non-dominant eye can be adjusted toward emmetropia via LASIK enhancement or piggyback IOL.
5. Acceptance rate: Studies show ~90% acceptance when the dominant eye is corrected for distance and the patient is well selected (Cataracts in the Adult Eye, p. 29).

8. Comparison of Modified vs. Conventional Monovision — Relevance to Selection

"Modified monovision (−0.75 D anisometropia) versus conventional monovision (−1.75 D or more anisometropia): binocular vision in relation to contrast sensitivity and stereopsis was better preserved with modified monovision, but near vision was compromised." — AAO BCSC Cataracts in the Adult Eye, p. 29

Summary Algorithm for Patient Selection

Patient desires spectacle independence with IOL
          ↓
Any absolute contraindication? (strabismus, macular/ON disease, amblyopia)
    YES → Not suitable for micromonovision
    NO  ↓
Prior successful monovision with CL/spectacles?
    YES → Strong candidate; proceed with contact lens simulation at surgical target
    NO  ↓
Perform binocular assessment + contact lens simulation trial (1–2 weeks)
    Tolerates well → Suitable for micromonovision (target −0.75 D non-dominant eye)
    Does not tolerate → Consider bilateral monofocal (emmetropia) or EDOF IOLs